Entrada Therapeutics raises $100M in registered direct offering to fund pipeline

Entrada Therapeutics, Inc.

Gross proceeds of $100M from sale of 3,367,003 shares at $14.85 and pre-funded warrants at $14.8499.
Offering led by U.S. healthcare-focused investor, two global mutual funds, and Janus Henderson.
Proceeds to fund Phase 2b trials for ENTR-601-44/45 and Phase 2 MAD trial for ENTR-601-50.
Expected closing on June 25, 2024; cash runway extended into 2027.
30-day lockup on new equity issuance and registration statements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.